We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels (ECSPLOIT -D)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2011 by TURRINI FABRIZIO, Azienda Unita' Sanitaria Locale Di Modena.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01477801
First Posted: November 23, 2011
Last Update Posted: November 23, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Abiogen Pharma
Information provided by (Responsible Party):
TURRINI FABRIZIO, Azienda Unita' Sanitaria Locale Di Modena
  Purpose

The purpose of this study is to determine whether cholecalciferol supplementation in patients with chronic heart failure and low vitamin D levels improves:

  1. performance at six minutes walking test
  2. echocardiographic parameters
  3. neurohormonal imbalance

Condition Intervention Phase
Heart Failure Vitamin D Deficiency Drug: CHOLECALCIFEROL Drug: PLACEBO Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels. A Phase 2 Randomized Double Blind Study

Resource links provided by NLM:


Further study details as provided by TURRINI FABRIZIO, Azienda Unita' Sanitaria Locale Di Modena:

Primary Outcome Measures:
  • SIX MINUTE WALKING TEST DISTANCE [ Time Frame: six months ]

Secondary Outcome Measures:
  • ECHOCARDIOGRAPHIC PARAMETERS [ Time Frame: six months ]
  • NEUROHORMONAL CHANGES [ Time Frame: six months ]

Estimated Enrollment: 34
Study Start Date: November 2011
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CHOLECALCIFEROL Drug: CHOLECALCIFEROL

Standard guideline based therapy plus cholecalciferol:

Loading dose 300.000 U then 50.000 U every month for six months

Other Name: DIBASE (ABIOGEN PHARMA)
Placebo Comparator: PLACEBO Drug: PLACEBO
Standard guideline based therapy plus placebo

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Heart failure diagnosis according to European Society of Cardiology Guideline criteria
  • Age > 60 years old
  • 25(OH) Vitamin D level < 30 ng/ml
  • Clinical and therapeutic stability for one month (NYHA class II or III)

Exclusion Criteria:

  • Chronic use of anticonvulsants or barbiturates, steroids, thiazides, aluminium or magnesium, colestipol or cholestyramine
  • Glomerular filtration rate lower than 30 ml/min/1.73 m2 according to MDRD equation
  • Nephrolitiasis, Sarcoidosis or hypercalcemia
  • Recent (three months) acute coronary syndrome or stroke or major vascular surgery
  • Reduced life expectancy due to other diseases (active neoplasms, liver cirrhosis...)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01477801


Contacts
Contact: Fabrizio Turrini, MD 0039593961100 f.turrini@ausl.mo.it

Locations
Italy
Medicina Cardiovascolare - NOCSAE - Azienda USL Recruiting
Modena, (mo), Italy, 41100
Contact: Fabrizio Turrini, MD    0039593961100    f.turrini@ausl.mo.it   
Sub-Investigator: Stefania Scarlini         
Sponsors and Collaborators
Azienda Unita' Sanitaria Locale Di Modena
Abiogen Pharma
Investigators
Principal Investigator: Fabrizio Turrini, MD Azienda USL di Modena
Study Director: Marco Bondi, MD Azienda USL di Modena
Study Chair: Paola Loria, MD Università di Modena
  More Information

Responsible Party: TURRINI FABRIZIO, MD, Azienda Unita' Sanitaria Locale Di Modena
ClinicalTrials.gov Identifier: NCT01477801     History of Changes
Other Study ID Numbers: MCV-MO-11-001
2011-001726-14 ( EudraCT Number )
First Submitted: November 18, 2011
First Posted: November 23, 2011
Last Update Posted: November 23, 2011
Last Verified: November 2011

Additional relevant MeSH terms:
Heart Failure
Vitamin D Deficiency
Heart Diseases
Cardiovascular Diseases
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Cholecalciferol
Vitamin D
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents